This inventor holds 28 USPTO granted patents and 16 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Inflazome Limited, Takeda Pharmaceutical Company Limited, Paradigm Therapeutics Ltd. Active years: 2008-2025.
Company Filing History:
19 out of 20 
8 out of 1,226 
1 out of 1 Years Active: 2008-2025
Areas of Expertise:
Title: David Miller: Innovator in Pharmaceutical Innovations
Introduction
David Miller, a prolific inventor located in Cambridge, GB, holds an impressive portfolio of 28 patents. His contributions to the field of pharmaceuticals, particularly in developing compounds for medical treatments, have established him as a prominent figure in innovation.
Latest Patents
Among his latest inventions are two noteworthy patents:
1. **Sulfonamide Carboxamide Compounds**: This invention pertains to sulfonylureas and sulfonylthioureas, which consist of a 5-membered heteroaryl group substituted with a monovalent heteroaryl-containing group. The invention also covers salts, solvates, and prodrugs of these compounds, alongside pharmaceutical compositions that feature them. These compounds have significant applications in the treatment and prevention of medical disorders, particularly through the inhibition of NLRP.
2. **Sulfonamideurea Compounds**: This patent relates to compounds of a specific formula where various cyclic groups and substituents play crucial roles. Similar to his first patent, this invention also addresses the development of salts, solvates, and prodrugs, as well as their use in pharmaceutical compositions. The focus remains on treating and preventing medical disorders, especially through inhibition of NLRP3.
Career Highlights
David has contributed his expertise while working with notable companies such as Inflazome Limited and Takeda Pharmaceutical Company Limited. His work has been pivotal in advancing research and development within these organizations.
Collaborations
Throughout his career, David has collaborated with talented professionals, including colleagues Matthew Cooper and Jonathan Shannon. Their collective efforts have driven innovation and have led to significant advancements in the health sector.
Conclusion
David Miller's innovative spirit and extensive patent portfolio reflect his commitment to improving medical treatments through his discoveries. His contributions continue to inspire future innovations within the pharmaceutical industry.